LENZ Q3 Sales Up 50% but CEO Exits as Reorg Targets 50% Cost Cut
LENZ is trading near its 52-week low of $3.06 (0.0% above the low).
Summary
VIZZ product sales hit $2.6 million in Q3, up about 50% from Q2 on over 38,000 paid prescriptions, with momentum carrying into Q4. But the company is restructuring hard: it targets 2027 operating expenses of roughly $70-75 million, more than 50% below prior plans, with about $5 million in non-recurring severance and termination charges, mostly in Q4 2026, and it has approved a strategic reorganization including a 75% headcount reduction to about 40 full-time employees. CEO Eef Schimmelpennink steps down December 1, 2026, and CFO Dan Chevallard takes over as Interim CEO. The quarter still showed a $31.0 million net loss and SG&A of $35.8 million, and cash fell to $197.3 million from $292.3 million at year-end 2025 — the burn is the reason for the cuts. The stock sits at its 52-week low, so the market has already been pricing skepticism on the launch; the reorganization and leadership change are the swing factors now. Q3 call is October 29 at 8:30 a.m. EDT.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — LENZ estimates about $5 million in non-recurring severance and termination charges, mostly in Q4 2026, and will cut headcount to about 40 full-time employees.
At the time of this announcement, LENZ was trading at $3.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $100.9M. The 52-week trading range was $3.06 to $32.13. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.